GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (OTCPK:TTNPW) » Definitions » Total Assets

Titan Pharmaceuticals (Titan Pharmaceuticals) Total Assets : $6.65 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Titan Pharmaceuticals Total Assets?

Titan Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was $6.65 Mil.

During the past 12 months, Titan Pharmaceuticals's average Total Assets Growth Rate was -52.80% per year. During the past 3 years, the average Total Assets Growth Rate was -20.80% per year. During the past 5 years, the average Total Assets Growth Rate was -26.50% per year. During the past 10 years, the average Total Assets Growth Rate was -14.60% per year.

During the past 13 years, Titan Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 150.90%. The lowest was -60.90%. And the median was -4.00%.

Total Assets is connected with ROA %. Titan Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 was -57.56%. Total Assets is also linked to Revenue through Asset Turnover. Titan Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.


Titan Pharmaceuticals Total Assets Historical Data

The historical data trend for Titan Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals Total Assets Chart

Titan Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.52 8.09 7.99 4.06 8.09

Titan Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.17 0.81 10.00 8.09 6.65

Titan Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Titan Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=6.642+1.444
=8.09

Titan Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=6.087+0.559
=6.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Titan Pharmaceuticals  (OTCPK:TTNPW) Total Assets Explanation

Total Assets is connected with ROA %.

Titan Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-4.24/( (8.086+6.646)/ 2 )
=-4.24/7.366
=-57.56 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Titan Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (8.086+6.646)/ 2 )
=0/7.366
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Titan Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Titan Pharmaceuticals (Titan Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.